Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cencora ( (COR) ) has issued an update.
Cencora, Inc., a global pharmaceutical solutions and distribution company that operates Retina Consultants of America as a physician-centered retina specialty network, focuses on improving access to therapies and supporting community care providers through logistics, commercialization and practice management services. The company leverages its scale and integrated offerings to deepen its presence in specialty care segments while maintaining an investment-grade financial profile.
On March 23, 2026, Cencora announced that it had signed a definitive agreement, dated March 21, 2026, to acquire EyeSouth Partners’ retina business for $1.1 billion, folding the affiliated retina physicians into its Retina Consultants of America platform. The deal, expected to be slightly accretive to adjusted diluted EPS in the first year after closing and leaving fiscal 2026 guidance unchanged, would expand Cencora’s footprint in retina care, strengthen its clinical trial and research capabilities, and further consolidate its position in physician-aligned ophthalmology services, subject to customary regulatory approvals and closing conditions.
The most recent analyst rating on (COR) stock is a Hold with a $363.00 price target. To see the full list of analyst forecasts on Cencora stock, see the COR Stock Forecast page.
Spark’s Take on COR Stock
According to Spark, TipRanks’ AI Analyst, COR is a Neutral.
The score is driven primarily by solid underlying business/cash-flow performance and a positive earnings update with raised fiscal 2026 guidance. Offsetting these positives are elevated balance-sheet leverage and weak near-term technical momentum, with valuation offering limited support at a higher P/E and low dividend yield.
To see Spark’s full report on COR stock, click here.
More about Cencora
Cencora is a leading global pharmaceutical solutions organization that partners with drug manufacturers across the value chain to optimize market access to therapies for people and animals worldwide. Ranked No. 10 on the Fortune 500 with more than $300 billion in annual revenue and over 51,000 employees, it provides secure distribution of pharmaceuticals, healthcare products and practice management support through units such as Retina Consultants of America.
Average Trading Volume: 1,230,888
Technical Sentiment Signal: Buy
Current Market Cap: $63.59B
See more insights into COR stock on TipRanks’ Stock Analysis page.